Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Insider Sells $213,879.54 in Stock

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) insider Jason R. Kelly sold 98,562 shares of the firm’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $2.17, for a total transaction of $213,879.54. Following the sale, the insider now directly owns 20,623,653 shares in the company, valued at approximately $44,753,327.01. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ginkgo Bioworks Trading Down 1.0 %

Shares of NYSE:DNA opened at $1.98 on Friday. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $1.94 and a twelve month high of $12.48. The firm’s 50 day moving average price is $2.71 and its 200-day moving average price is $2.82. The company has a current ratio of 11.71, a quick ratio of 11.67 and a debt-to-equity ratio of 0.04.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. IHT Wealth Management LLC raised its stake in Ginkgo Bioworks by 11.4% during the 3rd quarter. IHT Wealth Management LLC now owns 51,745 shares of the company’s stock worth $161,000 after acquiring an additional 5,275 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $2,856,000. Capital Impact Advisors LLC bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $118,000. Captrust Financial Advisors raised its stake in Ginkgo Bioworks by 113.1% during the 3rd quarter. Captrust Financial Advisors now owns 38,885 shares of the company’s stock worth $121,000 after acquiring an additional 20,635 shares during the period. Finally, Advisory Research Inc. raised its stake in Ginkgo Bioworks by 21.3% during the 3rd quarter. Advisory Research Inc. now owns 229,158 shares of the company’s stock worth $715,000 after acquiring an additional 40,237 shares during the period. Institutional investors own 53.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DNA. Raymond James dropped their price target on shares of Ginkgo Bioworks from $10.50 to $6.00 and set an “outperform” rating on the stock in a report on Tuesday. Morgan Stanley started coverage on shares of Ginkgo Bioworks in a research note on Tuesday, October 4th. They issued an “equal weight” rating and a $5.00 price objective on the stock. Finally, BTIG Research lowered their price objective on shares of Ginkgo Bioworks to $4.00 in a research note on Thursday, November 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Hold” and a consensus target price of $5.91.

About Ginkgo Bioworks

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Recommended Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.